JPWO2020203086A1 - - Google Patents

Info

Publication number
JPWO2020203086A1
JPWO2020203086A1 JP2021511318A JP2021511318A JPWO2020203086A1 JP WO2020203086 A1 JPWO2020203086 A1 JP WO2020203086A1 JP 2021511318 A JP2021511318 A JP 2021511318A JP 2021511318 A JP2021511318 A JP 2021511318A JP WO2020203086 A1 JPWO2020203086 A1 JP WO2020203086A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511318A
Other languages
Japanese (ja)
Other versions
JPWO2020203086A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020203086A1 publication Critical patent/JPWO2020203086A1/ja
Publication of JPWO2020203086A5 publication Critical patent/JPWO2020203086A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
JP2021511318A 2019-03-29 2020-03-10 Pending JPWO2020203086A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019065393 2019-03-29
PCT/JP2020/010232 WO2020203086A1 (ja) 2019-03-29 2020-03-10 Ｄ－アロースおよび／またはｄ－アルロースを含有してなる腹膜透析液の浸透圧調整剤

Publications (2)

Publication Number Publication Date
JPWO2020203086A1 true JPWO2020203086A1 (https=) 2020-10-08
JPWO2020203086A5 JPWO2020203086A5 (https=) 2022-03-11

Family

ID=72668623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021511318A Pending JPWO2020203086A1 (https=) 2019-03-29 2020-03-10

Country Status (7)

Country Link
US (1) US20220175931A1 (https=)
EP (1) EP3950057A4 (https=)
JP (1) JPWO2020203086A1 (https=)
CN (1) CN113710317A (https=)
BR (1) BR112021016283A2 (https=)
CA (1) CA3134085A1 (https=)
WO (1) WO2020203086A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097820A1 (en) * 2002-05-22 2003-11-27 Fushimi Pharmaceutical Co.,Ltd. Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用
JP2006008669A (ja) * 2004-05-24 2006-01-12 Kagawa Univ 植物または微生物への希少糖の使用
JP2007051135A (ja) * 2005-07-20 2007-03-01 Teikoku Seiyaku Co Ltd Ｄ−アロースの血糖上昇抑制効果の利用
JP2009269887A (ja) * 2008-05-09 2009-11-19 Kagawa Univ 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4943839B1 (https=) 1968-06-10 1974-11-25
JPS5330976B1 (https=) 1971-07-22 1978-08-30
JPS5317055B2 (https=) 1972-08-09 1978-06-06
US3991349A (en) 1975-01-03 1976-11-09 Westinghouse Electric Corporation Droop adjustable control apparatus for direct current motor drives
JPS5316164A (en) 1976-07-27 1978-02-14 Aisin Seiki Co Ltd Fluid coupling device
JPS589701B2 (ja) 1977-06-04 1983-02-22 株式会社栗本鉄工所 廃棄物処理装置
JPH1171273A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
JP4473980B2 (ja) 1999-06-24 2010-06-02 株式会社林原生物化学研究所 糖質複合体結晶とその製造方法
JP4499882B2 (ja) 2000-07-07 2010-07-07 株式会社林原生物化学研究所 Ｄ−キシロース・イソメラーゼを用いるアルドヘキソースの製造方法
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
JP2005102503A (ja) 2003-01-10 2005-04-21 Kagawa Univ 新しい触媒機能を有するｌ−ラムノースイソメラーゼの遺伝子配列およびその用途
JP4724824B2 (ja) 2004-03-19 2011-07-13 国立大学法人 香川大学 希少糖のｔリンパ球の増殖抑制への使用
US7691619B2 (en) 2004-08-24 2010-04-06 Rare Sugar Production Technical Research Laboratories, Llc Sequence of thermotolerant L-rhamnose isomerase gene and use of the same
EP1864669B1 (en) 2005-03-23 2018-06-27 Rare Sugar Production Technical Research Laboratories, LLC Application of d-psicose to suppression of abnormal circadian increase in blood glucose level
KR100744479B1 (ko) 2005-06-01 2007-08-01 씨제이 주식회사 사이코스 에피머화 효소에 의한 사이코스의 생산 방법
US8440619B2 (en) 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
WO2012011588A1 (ja) * 2010-07-23 2012-01-26 学校法人東海大学 腹膜透析患者用の経口医薬組成物及びその用法
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
JP5997693B2 (ja) 2011-07-06 2016-09-28 松谷化学工業株式会社 アルスロバクターグロビホルミスの生産する酵素

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097820A1 (en) * 2002-05-22 2003-11-27 Fushimi Pharmaceutical Co.,Ltd. Method of utilizing physiological activity of rare saccharide and compositions containing rare saccharide
JP2005213227A (ja) * 2004-01-30 2005-08-11 Teikoku Seiyaku Co Ltd Ｄ−プシコースの血糖上昇抑制効果の利用
JP2006008669A (ja) * 2004-05-24 2006-01-12 Kagawa Univ 植物または微生物への希少糖の使用
JP2007051135A (ja) * 2005-07-20 2007-03-01 Teikoku Seiyaku Co Ltd Ｄ−アロースの血糖上昇抑制効果の利用
JP2009269887A (ja) * 2008-05-09 2009-11-19 Kagawa Univ 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法

Also Published As

Publication number Publication date
BR112021016283A2 (pt) 2021-10-13
CN113710317A (zh) 2021-11-26
EP3950057A4 (en) 2022-12-28
CA3134085A1 (en) 2020-10-08
EP3950057A1 (en) 2022-02-09
US20220175931A1 (en) 2022-06-09
WO2020203086A1 (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021017728A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021021744A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021017310A2 (https=)
BR112021018484A2 (https=)
BR112021017949A2 (https=)
BR112021018084A2 (https=)

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230929

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240925

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241115